Tao Duan

Dr. Tao Duan


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2022 in Animals
Verified
Journal Article
Open access
PDF file
JAJishan An
Jishan An
JSJingjing Shi
Jingjing Shi
KLKuanbo Liu
Kuanbo Liu
ALAike Li
Aike Li
HBHe Beibei
He Beibei
JHJianhua He
Jianhua He
The study evaluated the effects of dry and wet solid-state fermented wheat bran (FWB) on growth performance, immune function, intestinal morphology and microflora in lipopolysaccharide (LPS)-challenged broiler chickens. The experiment was designed as a 2 × 3 factorial arrangement. A total of 252 one-day-old Arbor Acres male broiler chickens were randomly allocated to 1 of 6 treatments: basal diet + sterile saline (negative control, NC), basal diet + LPS (positive control, PC), 7% dry FWB + sterile saline (FWB-I), 7% dry FWB + LPS (FWB-II), 7% wet FWB + sterile saline (FWB-III) and 7% wet FWB + LPS (FWB-IV), with containing 6 replicate cages/treatment and 7 broiler chickens/cage, and the experimental period lasted for 42 days. Broilers were intraperitoneally injected with either 0.5 mg LPS or sterile saline solution per kg body weight at 16, 18 and 20 d of age. Growth performance, serum immunological parameters and indicators related to intestinal health were analyzed on days 21 and 42. Compared with NC, dry and wet FWB significantly increased (p < 0.05) average daily feed intake of days 21 to 42, and increased (p < 0.05) the villus height and villus height to crypt depth ratio of ileum on day 21, decreased (p = 0.101) the jejunum crypt depth and decreased (p < 0.05) the Lactobacillus and Bifidobacterium counts of the cecum digesta on day 42. Compared with NC, FWB-II and FWB-IV significantly increased (p < 0.05) the levels of serum total protein and globulin on day 21; compared with the basal diet groups, dry and wet FWB groups significantly increased (p < 0.05) glucose levels on day 21, and wet FWB significantly decreased (p < 0.05) alanine aminotransferase levels on day 42. Compared with PC and FWB-II, FWB-IV significantly increased (p < 0.05) the level of serum immunoglobulin G on day 21. Compared with PC and FWB-II, FWB-IV significantly decreased (p < 0.05) the levels of serum pro-inflammatory cytokines interleukin (IL)-6, IL-8, IL-1β and acute C reactive protein (CRP) on day 21; compared with FWB-III, FWB-IV significantly decreased (p < 0.05) the levels of IL-6, IL-8, CRP and tumor necrosis factor alpha on day 42, but the levels of IL-4 and IL-10 were significantly increased (p < 0.05) on days 21 and 42. These results indicated that supplementing 7% dry or wet FWB can improve growth performance and serum immune functions of broilers, which effectively alleviate the LPS-challenged damage, and wet FWB had a better effect than dry FWB.

15 April 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
HBHe Beibei
He Beibei
TDTao Duan
Tao Duan
DHDandan Hu
Dandan Hu
LCLixian Chen
Lixian Chen
LQLin Qiao
Lin Qiao
ALAike Li
Aike Li
Background/Objectives: Lactobacillus strains are widely used as probiotics in the functional food industry and show potential for treating inflammatory bowel disease (IBD). However, the strain specificity and limited stress resistance of Lactobacillus restricts its therapeutic effectiveness. The aim of this study was to investigate the effects of dietary supplementation with microencapsulated Lactobacillus plantarum 17-1 on the intestinal immune responses, gut microbiota composition, and metabolic characteristics in colitis mice. Methods: Mice were pre-fed a diet containing microencapsulated Lactobacillus plantarum 17-1 for 3 weeks and then treated with 2.5% dextran sulfate sodium (DSS) in drinking water for 8 days to induce colitis. Results: The results showed that microencapsulated Lactobacillus plantarum 17-1 effectively alleviated clinical symptoms and histopathological features of colitis mice and suppressed the up-regulation of pro-inflammatory cytokines IL-6 and IL-17 in the colon of colitis mice. Additionally, Lactobacillus plantarum 17-1 significantly increased the relative abundance of several beneficial bacterial taxa, including Ruminococcaceae_UCG_014, Bacteroides, Prevotellaceae_UCG_001, Lactococcus, Weissella, Pediococcus, and so on. Moreover, it regulated the levels of multiple inflammation-related metabolites involved in linolenic acid metabolism, arachidonic acid metabolism, primary bile acid biosynthesis, and tyrosine metabolism. Conclusions: These results suggest that dietary supplementation with microencapsulated Lactobacillus plantarum 17-1 reduced colitis inflammation in mice by modulating the intestinal microbiota composition and metabolic characteristics, which may serve as a potential therapeutic strategy for IBD.

13 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
HBHe Beibei
He Beibei
TDTao Duan
Tao Duan
DHDandan Hu
Dandan Hu
LQLin Qiao
Lin Qiao
LQLin Qiao
Lin Qiao
ALAike Li
Aike Li
Background/Objectives: Lactobacillus strains are widely used as probiotics in the functional food industry and show potential for treating inflammatory bowel disease (IBD). The aim of this study was to investigate the effects of dietary supplementation with microencapsulated Lactobacillus plantarum 17-1 on the intestinal immune response and gut microbiota in mice with colitis. Methods: Mice were pre-fed a diet containing microencapsulated Lactobacillus plantarum 17-1 for three weeks, followed by colitis induction using 2.5% dextran sulfate sodium (DSS) in drinking water for 8 days. Results: Lactobacillus plantarum 17-1 significantly improved clinical symptoms and histopathological features in colitis-affected mice. Additionally, it effectively suppressed the up-regulation of pro-inflammatory cytokines IL-6 and IL-17 in the colon tissue of the mice. The probiotic administration increased the linear discriminant analysis score for several beneficial bacterial taxa, including Ruminococcaceae_UCG_014, Bacteroides, Prevotellaceae_UCG_001, Lactococcus, Weissella, Pediococcus, and so on. Also, Lactobacillus plantarum 17-1 regulated the abundance of inflammation-related metabolites which involved in linolenic acid metabolism, arachidonic acid metabolism, primary bile acid biosynthesis and tyrosine metabolism. Conclusions: These findings indicate that microencapsulated Lactobacillus plantarum 17-1 has a significant anti-inflammatory effect in the DSS-induced colitis model and may serve as a potential therapeutic strategy for IBD.